Abstract P1-08-06: Low tumor CD68 mRNA content (intratumoral macrophages) is predictive for benefit from adjuvant trastuzumab in HER2-positive breast cancer: An analysis of the FinHER trial

Mrna Content ◽

Faculty Opinions recommendation of 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718043513.793482079 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Her2 Positive ◽

Open Label ◽

Adjuvant Trastuzumab ◽

Randomised Controlled ◽

Adjuvant Trastuzumab in HER2-Positive Breast Cancer: Observational Monocentric Study of 84 Cases

Annals of Oncology ◽

10.1093/annonc/mdt079.3 ◽

2013 ◽

Vol 24 ◽

pp. iii16

Author(s):

M. Aitelhaj ◽

S. Lkhoyaali ◽

G. Rais ◽

A. Mohtaram ◽

S. Boutayeb ◽

...

Keyword(s):

Breast Cancer ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab

Medical Molecular Morphology ◽

10.1007/s00795-018-0208-9 ◽

2018 ◽

Vol 52 (2) ◽

pp. 106-113

Author(s):

Naoki Kanomata ◽

Junichi Kurebayashi ◽

Takuya Moriya

Keyword(s):

Breast Cancer ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer

Korean Journal of Clinical Oncology ◽

10.14216/kjco.18019 ◽

2018 ◽

Vol 14 (2) ◽

pp. 108-115

Author(s):

Ashraf Mahmoud El-Enbaby ◽

Nadia Ahmed Abd El Moneim ◽

Gehan Abd El atti Khedr ◽

Yasmine Mohamed Nagy Elwany

Keyword(s):

Breast Cancer ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Abstract PS10-58: Cost effectiveness of routine cardiac imaging during adjuvant trastuzumab in HER2-positive breast cancer

10.1158/1538-7445.sabcs20-ps10-58 ◽

2021 ◽

Author(s):

Vineeth Tatineni ◽

Daniel Redle ◽

Daljeet Singh ◽

Arifa Abid ◽

Sameer Mahesh

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Cardiac Imaging ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

226P Impact of BMI on outcome and cardiac safety in HER2-positive breast cancer patients treated with adjuvant trastuzumab: Results of a monocentric observational study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.347 ◽

2020 ◽

Vol 31 ◽

pp. S331

Author(s):

C. Molinelli ◽

L. Del Mastro ◽

S. Giraudi ◽

A. Ballestrero ◽

F. Carli ◽

...

Keyword(s):

Breast Cancer ◽

Observational Study ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Cardiac Safety ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy

PharmacoEconomics ◽

10.1007/s40273-018-0634-5 ◽

2018 ◽

Vol 36 (4) ◽

pp. 505-505

Author(s):

Amir Ansaripour ◽

Carin A. Uyl-de Groot ◽

W. Ken Redekop

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Scenario Analysis ◽

Treatment Strategy ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Trastuzumab Therapy ◽

Optimal Treatment Strategy ◽

Abstract P4-12-20: Clinical outcomes of patients with recurrent HER2-positive breast cancer after exposure to adjuvant trastuzumab

10.1158/0008-5472.sabcs13-p4-12-20 ◽

2013 ◽

Author(s):

DN Mullins ◽

M Abdel-Rasoul ◽

J Querry ◽

D Akuma ◽

A Feng ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Outcomes ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Abstract 5295: Impact of a multi-gene expression profile in predicting adjuvant trastuzumab outcome in HER2-positive breast cancer

10.1158/1538-7445.am2020-5295 ◽

2020 ◽

Author(s):

Sara Ravaioli ◽

Roberta Maltoni ◽

Francesca Pirini ◽

Michela Palleschi ◽

William Balzi ◽

...

Keyword(s):

Breast Cancer ◽

Gene Expression ◽

Gene Expression Profile ◽

Expression Profile ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Abstract P5-10-18: The chromosomal genomic landscape and targetable co-amplified genes in HER2 positive breast cancer patients who relapsed on an adjuvant trastuzumab chemotherapy trial

10.1158/1538-7445.sabcs14-p5-10-18 ◽

2015 ◽

Author(s):

Shelly Gunn ◽

Chris McCaskill ◽

Linda Daley ◽

Agnes Puskas ◽

Lina Asmar ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Genomic Landscape ◽